TIM-3 was initially considered as well, due to its relevance in AML immunosuppression and prominent expression of Gal-9 in the target cells but was eventually not evaluated due to its low expression in the effector NK-92 cell lines (Figure 2b) [32]. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.